WO1994008630A1 - Novel compositions for magnetic resonance imaging - Google Patents

Novel compositions for magnetic resonance imaging Download PDF

Info

Publication number
WO1994008630A1
WO1994008630A1 PCT/US1993/009868 US9309868W WO9408630A1 WO 1994008630 A1 WO1994008630 A1 WO 1994008630A1 US 9309868 W US9309868 W US 9309868W WO 9408630 A1 WO9408630 A1 WO 9408630A1
Authority
WO
WIPO (PCT)
Prior art keywords
chr
iii
group
conr
members
Prior art date
Application number
PCT/US1993/009868
Other languages
French (fr)
Inventor
Dennis A. Moore
Rebecca A. Wallace
Muthunadar P. Periasamy
Original Assignee
Mallinckrodt Medical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Medical, Inc. filed Critical Mallinckrodt Medical, Inc.
Priority to AU53609/94A priority Critical patent/AU5360994A/en
Publication of WO1994008630A1 publication Critical patent/WO1994008630A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/12Macromolecular compounds

Definitions

  • This invention relates to magnetic resonance imaging agents, and more particularly to methods and compositions for enhancing magnetic resonance imaging.
  • MRI magnetic resonance imaging
  • CT X-ray computed tomography
  • the images produced constitute a map of the distribution density of protons and/or the relaxation times in organs and tissues.
  • the technique of MRI is advantageo sly non-invasive as it avoids the use of ionizing radiation.
  • nuclei with appropriate spin when placed in an applied magnetic field align in the direction of the field.
  • B expressed generally in units of gauss or Tesla (10 4 gauss)
  • these nuclei precess at a frequency, F, of 42.6 MHz at a field strength of 1 Tesla.
  • F a frequency
  • an RF pulse of radiation will excite the nuclei and can be considered to tip the net magnetization out of the field direction, the extend of this rotation being determined by the pulse, duration and energy.
  • the nuclei "relax" or return to equilibrium with the magnetic field, emitting radiation at the resonant frequency.
  • the decay of the emitted radiation is characterized by two relaxation times, i.e., T 1 , the spin-lattice relaxation time or longitudinal relaxation time, that is, the time taken by the nuclei to return to equilibrium along the direction of the externally applied magnetic field, and T 2 , the spin-spin relaxation time associated with the dephasing of the initially coherent precession of individual proton spins.
  • T 1 the spin-lattice relaxation time or longitudinal relaxation time, that is, the time taken by the nuclei to return to equilibrium along the direction of the externally applied magnetic field
  • T 2 the spin-spin relaxation time associated with the dephasing of the initially coherent precession of individual proton spins.
  • MRI may be capable of differentiating different tissue types and in detecting diseases which induce physicochemical changes that may not be detected by X-Ray or CT which are only sensitive to differences in the electron density of tissue.
  • T 1 and T 2 two of the principal imaging parameters are the relaxation times, T 1 and T 2 .
  • these relaxation times are influenced by the environment of the nuclei (e.g., viscosity, temperature, and the like).
  • These two relaxation phenomena are essentially mechanisms whereby the initially imparted radio-frequency energy is dissipated to the surrounding environment.
  • the rate of this energy loss or relaxation can be influenced by certain other nuclei which are paramagnetic.
  • Chemical compounds incorporating these paramagnetic nuclei may substantially alter the T 1 and T 2 values for nearby protons.
  • the extent of the paramagnetic effect of the given chemical compound is a function of the environment within which it finds itself.
  • paramagnetic ions of elements with an atomic number of 21 to 29, 42 to 44 and 58 to 70 have been found effective as MRI contrasting agents.
  • Suitable such ions include chromium (III), manganese (II), manganese (III), iron (III), iron (II), cobalt (II), nickel (II), copper (II), praseodymium (III), neodymium (III), samarium (III) and ytterbium (III). Because of their very strong magnetic moments, gadolinium (III), terbium (III), dysprosium (III), holmium (III) and erbium (III) are preferred. Gadolinium (III) ions have been particularly preferred as MRI contrasting agents.
  • the divalent and trivalent paramagnetic ions have been administered in the form of complexes with organic complexing agents.
  • complexes provide the paramagnetic ions in a soluble, non-toxic form, and facilitate their rapid clearance from the body following the imaging procedure.
  • Gries, et al., U.S. Patent 4,647,447 disclosed complexes of various paramagnetic ions with conventional aminocarboxylic acid complexing agents.
  • a preferred complex disclosed by Gries, et al. is a complex of gadolinium (III) with diethylenetriaminepentaacetic acid (“DTPA"). DTPA is represented by the formula:
  • Paramagnetic ions such as gadolinium (III) have been found to form strong complexes with other polyamino-carboxylic acids such as, cyclohexanediaminetetraacetic acid (“CDTA”) represented by the formula: and tetraazacyclododecane-N,N', N" , N' " -tetraacetic acid ( "DOTA” ) represented by the formula:
  • CDTA cyclohexanediaminetetraacetic acid
  • DOTA tetraazacyclododecane-N,N', N" , N' " -tetraacetic acid
  • complexes do not dissociate substantially in physiological aqueous fluids.
  • the complexes have a net charge of -1 or -2, and generally are administered as soluble salts. Typical such salts are the sodium and N-methylglucamine salts.
  • ionizable salts are attended by certain disadvantages. These salts can raise the in vivo ion concentration and cause localized disturbances in osmolality, which in turn, can lead to edema and other undesirable reactions.
  • the nature of the derivative used to convert carboxylic acid groups to non-ionic groups can have a significant impact on solubility.
  • derivatizing the carboxylic acid groups with hydrophobic alkylamide groups substantially decreases the water solubility of the complex.
  • the solubility of the complex in physiological fluids can, in turn, affect the tissue selectivity of the complex.
  • Hydrophilic complexes tend to concentrate in the interstitial fluids, whereas hydrophobic complexes tend to associate with cells.
  • differences in hydrophilicity can lead to different applications of the compounds. See, for example, Weinmann, et al., AJR, 142, 679 (Mar. 1984) and Brasch, et al., AJR, 142, 625 (Mar. 1984).
  • the present invention provides novel complexing agents and complexes of complexing agents with paramagnetic ions for use in MRI.
  • the complexes are represented by the two following general formulas:
  • A is selected from the group consisting of
  • R 8 is selected from the group consisting of -O-, -NR 4 OR 5 , -NR 4 O(CH 2 ) n R 6 ,
  • R 1 , R 2 and R 3 groups may be the same or different selected from the group consisting of hydrogen, C 1-8 alkyl -such as for example methyl or ethyl wherein methyl is preferable to minimize lipophilicity, C 1-8 alkoxy -such as for example methoxy or ethoxy, C 1-8 mono- or poly- hydroxyalkyl -such as for example hydroxymethyl or dihydroxypropyl wherein dihydroxypropyl is preferred to enhance water solubility, C 1-8 alkylalkoxy -such as for example methylmethoxy, C 1-8 alkoxyalkyl - such as for example methoxymethyl or methoxyethyl wherein
  • methoxymethyl is preferred to reduce lipophilicity, and C 5-8 aryl - such as for example phenyl or benzyl, or wherein R 2 and R 3 as defined above together with the intervening carbon form a hydrocarbon ring of 5, 6 or 7 members.
  • R 8 substituents examples include but are not limited to:
  • R 4 , R 5 , R 6 and R 7 groups may be the same or different selected from the group consisting of hydrogen, C 1-8 alkyl -such as for example methyl or ethyl wherein methyl is preferable to minimize lipophilicity, hydroxy, C 1-8 alkoxy -such as for example methoxy or ethoxy , C 1-8 mono- or poly- hydroxyalkyl -such as for example hydroxymethyl or dihydroxypropyl wherein dihydroxypropyl is preferred to enhance water solubility, C 1-8 alkoxyalkyl -such as for example methoxymethyl or methoxyethyl wherein methoxymethyl is preferred to reduce lipophilicity, C 1-8 aminoalkyl -such as for example aminomethyl, C 5-10 aryl -such as for example phenyl or benzyl, C 5-10 substituted aryl -such as for example aminophenyl or iodophenyl and C 1-12 acylaminoalkyl
  • C 1-8 alkyl - such as for example methyl or ethyl wherein methyl is preferable to reduce lipophilicty
  • C 5-10 aryl - such as for example phenyl or benzyl
  • C 5-10 aminoaryl - such as for example aminophenyl or aminobenzyl
  • hydroxy, C 1-8 alkoxy - such as for example methoxy or ethoxy
  • C 1-8 mono- or poly- hydroxyalkyl - such as for example hydroxymethyl or hydroxyethyl
  • C 1-8 alkoxyalkyl - such as for example methoxymethyl or methoxyethyl
  • C 1-8 aminoalkyl - such as for example aminomethyl or aminoethyl
  • carbamoyl and C 1-12 acylaminoalkyl - such as for example acetylaminomethyl or propanoylaminomethyl
  • n is an integer between 0 and 10
  • M z such as for example acet
  • M z+ is a heavy metal ion, such complexes can be used as X-ray contrast agents; if M z+ is a radioactive isotope the complexes may be used as diagnostic or therapeutic agents in nuclear medicine.
  • the compounds of the present invention may also be attached to a biomolecule or polymeric compound.
  • biomolecules such as hormones, proteins, lipids, albumins, polyhydroxyl compounds such as amino sugars, carbohydrates and polylysines to name a few.
  • the compounds of the present invention are attached to such a polymeric compound through the carboxyl group of the complexing acid or by other conventional methods.
  • the compounds of the present invention may also be carried by liposomes such as unilamellar or multilamellar vesicles and by other drug delivery systems.
  • a diagnostic composition and a method of performing a diagnostic procedure which involves administering to a warm-blooded animal an effective amount of the above-described complex and then exposing the warm-blooded animal to a diagnostic procedure, thereby imaging at least a portion of the body of the warm-blooded animal.
  • the complexing agents employed in this invention are derivatives of the well-known chelating agents such as DTPA, EDTA, CDTA or DOTA.
  • these derivatives one or more of the carboxylic acid groups are converted to amide groups.
  • the paramagnetic ion is trivalent, one or two of the carboxylic acid groups of DTPA may be derivatized to the amide form.
  • the paramagnetic ion is divalent, one to three of the carboxylic acid groups of DTPA may be derivatized to the amide form.
  • derivatives of other chelating agents such as EDTA, CDTA or DOTA were to be used.
  • the amide derivatives of chelating agents such as DTPA, EDTA, CDTA or DOTA are prepared in a conventional manner. In general, they are prepared by reacting a stoichiometric amount of a desired amine with a reactive derivative of a chelating agent under amide-forming conditions.
  • reactive derivatives include, for example, anhydrides, mixed anhydrides and acid chlorides.
  • the reactions are conducted in an organic solvent at an elevated temperature.
  • Suitable solvents include those in which the reactants are sufficiently soluble and which are substantially unreactive with' the reactants and products.
  • Lower aliphatic alcohols, ketone, ethers, esters, chlorinated hydrocarbons, toluene, xylene, lower aliphatic hydrocarbons, and the like may be advantageously used as reaction solvents.
  • reaction solvents examples include methanol, ethanol, 2-propanol, 2-butanol, acetone, methylethylketone, diethylketone, methylacetate, ethylacetate, chloroform, methylenechloride, dichloroethane, hexane, heptane, octane, decane, and the like.
  • the reaction solvent advantageously is one which does not contain reactive functional groups, such as hydroxyl groups, as these solvents can react with the acid chlorides, thus producing unwanted byproducts.
  • the reaction temperature may vary widely, depending upon the starting materials employed, the nature of the reaction solvent and other reaction conditions. Such reaction temperatures may range, for example, from about 0°C to about 150°C preferably from about 30°C to about 70°C.
  • any remaining anhydride or acid chloride groups can be hydrolyzed to the carboxylic groups by adding a stoichiometric excess of water to the reaction mixture and heating for a short time.
  • the resulting DTPA, EDTA, CDTA or DOTA amide is recovered from the reaction mixture by conventional procedures.
  • the product may be precipitated by adding a precipitating solvent to the reaction mixture and recovered by filtration or centrifugation.
  • the paramagnetic ion is then combined with the above isolated amide derivative under complex-forming conditions.
  • any of the paramagnetic ions referred to above can be employed in making the complexes of this invention.
  • the complexes can conveniently be prepared by mixing a suitable oxide or salt to the paramagnetic ion with the complexing agent in aqueous solution. To assure complete complex formation, a slight stoichiometric excess of the complexing agent may be used.
  • an elevated temperature e.g., ranging from about 20°C to about 100°C, preferably from about 40°C to about 80°C, may be employed to insure complete complex formation. Generally, complete complex formation will occur within a period from a few minutes to a few hours after mixing.
  • the complex may be recovered by precipitation using a precipitating solvent such as acetone, and further purified by crystallization, if desired.
  • the novel complexes of this invention can be formulated into diagnostic compositions for enteral or parenteral administration. These compositions contain an effective amount of the paramagnetic ion complex along with conventional pharmaceutical carriers and excipients appropriate for the type of administration contemplated.
  • parenteral formulation advantageously contain a sterile aqueous solution or suspension of from about 0.05 to 1.0M of a paramagnetic ion complex according to this invention.
  • Preferred parental formulations have a concentration of paramagnetic ion complex of 0.1M to 0.5M.
  • compositions may further contain physiologically acceptable non-toxic cations in the form of suitable organic or inorganic salts, including suitable soluble complex salts with a chelate/ligand to enhance safety.
  • physiologically acceptable non-toxic cations include the ligands set forth above used to complex paramagnetic and/or heavy metals to provide the complex formulations of this invention.
  • the cation-ligand complex salt is provided in amounts ranging from about 0.001 Mol percent to about 15 Mol percent excess, of the ligand-metal complex.
  • physiologically acceptable non-toxic cations include sodium ions, calcium ions, magnesium ions, copper ions, zinc ions and the like including mixtures thereto. Calcium ions are preferred.
  • Parenteral compositions may be injected directly or mixed with a large volume parenteral composition for systemic administration.
  • Formulations for enteral administration may vary widely, as is well-known in the art.
  • such formulations are ligands which include an effective amount of the paramagnetic ion complex in aqueous solution or suspension.
  • Such enteral compositions may optionally include buffers, surfactants, thixotropic agents, and the like.
  • Compositions for oral administration may also contain flavoring agents and other ingredients for enhancing their organoleptic qualities.
  • the diagnostic compositions are administered in doses effective to achieve the desired enhancement of the MR image.
  • doses may vary widely, depending upon the particular paramagnetic ion complex employed, the organs or tissues which are the subject of the imaging procedure, the MR imaging equipment being used, etc.
  • parenteral dosages will range from about 0.01 to about 1.0 MMol of paramagnetic ion complex per kilogram of patient body weight.
  • Preferred parenteral dosage range from about 0.05 to about 0.5 MMol of the paramagnetic ion complex per kilogram of patient body weight.
  • Enteral dosages generally range from about 0.5 to about 100 MMol, preferably from about 1.0 to about 20 MMol of paramagnetic ion complex per kilogram of patient body weight.
  • the novel MRI contrasting agents of this invention possess a unique combination of desirable features.
  • the paramagnetic ion complexes exhibit a high solubility in physiological fluids, notwithstanding in some cases their substantially non-ionic character. This high solubility allows the preparation of concentrated solutions, thus minimizing the amount of fluid required to be administered. In selected cases the non-ionic character of the complex also reduces the osmolality of the diagnostic compositions, thus preventing undesired edema and other side effects.
  • compositions of this invention are used in the conventional manner.
  • Compositions may be administered in a sufficient amount to provide adequate visualization, to a warm-blooded animal either systemically or locally to an organ or tissues to be imaged, and the animal then subjected to the MRI procedure.
  • the compositions have been found to enhance the magnetic resonance images obtained by these procedures.
  • the complexing agents of this invention may also be employed for delivery of radiopharmaceuticals or heavy metals for X-Ray contrast into the body.
  • the invention is further illustrated by the following examples, which are not intended to be limiting.
  • the first step is a modified Schotten-Baumann acetylation of 2-methoxy-ethyl amine.
  • the chloroamide, 1, is readily purified by vacuum distillation (1 torr, 58°C).
  • methylamine is N-alkylated with the chloroamide.
  • the resulting N-methylglycine(2-methoxyethylamide), 2 is also purified by vacuum distillation (1 torr, 28°C).
  • Reaction of the glycinamide with diethylenetriaminepentaacetic dianhydride in 2-propanol gives the desired bis(amide) of DTPA, 3.
  • Complexation of the ligand with gadolinium gives the complex, 4.
  • the complex is purified by reverse phase flash chromatography.
  • the ligand is used "as is" for complexometric reactions.
  • a small sample was purified by reverse phase flash column chromatography. IR(cm -1 ) C-O 1724 (m,sh), 1659 (vs,). Anal. Calc. %C 48.07, %H 7.29, %N 15.09. Found %C 47.77, %H 7.04, %N 15.39.
  • a 1L round bottom flask was charged with 34g (assuming 30.9g, 0.048mole anhydrous ligand present) crude ligand, 3, 8.6g (0.024mole) gadolinium oxide and 500mL water. The mixture was heated to gentle reflux and stirred overnight. The slightly turbid yellow mixture was filtered (0.42 micron) and concentrated to 50mL by rotary evaporator with a water aspirator. The thick clear solution was applied to a 5 ⁇ 35cm column loaded with YMC C-18 reverse phase packing. The column was eluted with water.
  • the mouse i .v . LD 50 value of a 0 . 5M solution of ⁇ Aqua (N, N" -bis ( N" " -2 -methoxyethylcarbamoylmethyl -N ' " -methylcarbamoylmethyl)diethylenetriamine-N,N',N"-triacetate) ⁇ gadolinium( III) was determined to be 32 .5 mmol/kg (confidence limit of 27.3 - 38.8 mmol/kg) and the relaxivity rates (mmol -1 sec -1 ) were obtained using the Bruker NMR Minispec (20 MHz) spectrometer at 40°C in both sterile water for injection (SWFI) and 4% bovine serum albumin (BSA): R 1 : SWFI, 4.3; BSA, 4.6; R 2 : SWFI, 4.1; BSA, 5.3.
  • SWFI Bruker NMR Minispec
  • Gadolinium oxide (1.91 g, 5.27 m mol) was added to (7) (7.2 g, 10.6 m mol) in 50 ml of water. The mixture was stirred at 69°-71°C overnight. The solution was filtered and water was removed by rotary evaporation. The crude product (8) (9.2 g, 103.4%) was a white powder.

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Methods and compositions for enhancing magnetic resonance imaging in at least a portion of a warm-blooded animal.

Description

NOVEL COMPOSITIONS FOR MAGNETIC RESONANCE IMAGING
Background of the Invention
This invention relates to magnetic resonance imaging agents, and more particularly to methods and compositions for enhancing magnetic resonance imaging.
The recently developed technique of magnetic resonance imaging (MRI) encompasses the detection of certain atomic nuclei utilizing magnetic fields and radio-frequency radiation. It is similar in some respects to X-ray computed tomography (CT) in providing a cross-sectional display of the body organ anatomy with excellent resolution of soft tissue detail. As currently used, the images produced constitute a map of the distribution density of protons and/or the relaxation times in organs and tissues. The technique of MRI is advantageo sly non-invasive as it avoids the use of ionizing radiation.
While the phenomenon of MRI was discovered in 1945, it is only relatively recently that it has found application as a means of mapping the internal structure of the body as a result of the original suggestion of Lauterbur (Nature, 242, 190-191 (1973)). The fundamental lack of any known hazard associated with the level of the magnetic and radio-frequency fields that are employed renders it possible to make repeated scans on vulnerable individuals. Additionally, any scan plane can readily be selected, including transverse, coronal and sagittal sections. In an MRI experiment, the nuclei under study in a sample (e.g. protons) are irradiated with the appropriate radio-frequency (RF) energy in a controlled gradient magnetic field. These nuclei, as they relax, subsequently emit RF energy at a sharp resonance frequency. The resonance frequency of the nuclei depends on the applied magnetic field.
According to known principles, nuclei with appropriate spin when placed in an applied magnetic field (B, expressed generally in units of gauss or Tesla (104 gauss)) align in the direction of the field. In the case of protons, these nuclei precess at a frequency, F, of 42.6 MHz at a field strength of 1 Tesla. At this frequency, an RF pulse of radiation will excite the nuclei and can be considered to tip the net magnetization out of the field direction, the extend of this rotation being determined by the pulse, duration and energy. After the RF pulse, the nuclei "relax" or return to equilibrium with the magnetic field, emitting radiation at the resonant frequency. The decay of the emitted radiation is characterized by two relaxation times, i.e., T1, the spin-lattice relaxation time or longitudinal relaxation time, that is, the time taken by the nuclei to return to equilibrium along the direction of the externally applied magnetic field, and T2, the spin-spin relaxation time associated with the dephasing of the initially coherent precession of individual proton spins. These relaxation times have been established for various fluids, organs and tissues in different species of mammals.
In MRI, scanning planes and sliced thicknesses can be selected. This selection permits high quality transverse, coronal and sagittal images to be obtained directly. The absence of any moving parts in MRI equipment promotes a high reliability. It is believed that MRI has a greater potential than CT for the selective examination of tissue characteristics. The reason for this being that in CT, X-ray attenuation and coefficients alone determine image contrast, whereas at least four separate variables (T1, T2, proton density and flow) may contribute to the MRI signal. For example, it has been shown (Damadian, Science, 171, 1151 (1971)) that the values of the T1 and T2 relaxation in tissues are generally longer by about a factor of two (2) in excised specimens of neoplastic tissue compared with the host tissue.
By reason of its sensitivity to subtle physiochemical differences between organs and/or tissues, it is believed that MRI may be capable of differentiating different tissue types and in detecting diseases which induce physicochemical changes that may not be detected by X-Ray or CT which are only sensitive to differences in the electron density of tissue.
As noted above, two of the principal imaging parameters are the relaxation times, T1 and T2. For protons (or other appropriate nuclei), these relaxation times are influenced by the environment of the nuclei (e.g., viscosity, temperature, and the like). These two relaxation phenomena are essentially mechanisms whereby the initially imparted radio-frequency energy is dissipated to the surrounding environment. The rate of this energy loss or relaxation can be influenced by certain other nuclei which are paramagnetic. Chemical compounds incorporating these paramagnetic nuclei may substantially alter the T1 and T2 values for nearby protons. The extent of the paramagnetic effect of the given chemical compound is a function of the environment within which it finds itself. In general, paramagnetic ions of elements with an atomic number of 21 to 29, 42 to 44 and 58 to 70 have been found effective as MRI contrasting agents. Suitable such ions include chromium (III), manganese (II), manganese (III), iron (III), iron (II), cobalt (II), nickel (II), copper (II), praseodymium (III), neodymium (III), samarium (III) and ytterbium (III). Because of their very strong magnetic moments, gadolinium (III), terbium (III), dysprosium (III), holmium (III) and erbium (III) are preferred. Gadolinium (III) ions have been particularly preferred as MRI contrasting agents.
Typically, the divalent and trivalent paramagnetic ions have been administered in the form of complexes with organic complexing agents. Such complexes provide the paramagnetic ions in a soluble, non-toxic form, and facilitate their rapid clearance from the body following the imaging procedure. Gries, et al., U.S. Patent 4,647,447, disclosed complexes of various paramagnetic ions with conventional aminocarboxylic acid complexing agents. A preferred complex disclosed by Gries, et al., is a complex of gadolinium (III) with diethylenetriaminepentaacetic acid ("DTPA"). DTPA is represented by the formula:
Figure imgf000006_0001
Paramagnetic ions, such as gadolinium (III), have been found to form strong complexes with other polyamino-carboxylic acids such as, cyclohexanediaminetetraacetic acid ("CDTA") represented by the formula:
Figure imgf000007_0001
and tetraazacyclododecane-N,N', N" , N' " -tetraacetic acid ( "DOTA" ) represented by the formula:
Figure imgf000007_0002
These complexes do not dissociate substantially in physiological aqueous fluids. The complexes have a net charge of -1 or -2, and generally are administered as soluble salts. Typical such salts are the sodium and N-methylglucamine salts.
The administration of ionizable salts is attended by certain disadvantages. These salts can raise the in vivo ion concentration and cause localized disturbances in osmolality, which in turn, can lead to edema and other undesirable reactions.
Efforts have been made to design non-ionic paramagnetic ion complexes. In general, this goal has been achieved by converting one or more of the free carboxylic acid groups of the polyamino acid type ligands such as EDTA or DTPA to neutral, non-ionizable groups. For example, S. C. Quay, in U.S. Patents 4,687,658 and 4,687,659, discloses alkylester and alkylamide derivatives respectively, of DTPA complexes. Similarly, published Dean et al., U.S. Patent 4,826,673 discloses mono- and polyhydroxyalkylamide derivatives of DTPA and their use as complexing agents for paramagnetic ions.
The nature of the derivative used to convert carboxylic acid groups to non-ionic groups can have a significant impact on solubility. For example, derivatizing the carboxylic acid groups with hydrophobic alkylamide groups substantially decreases the water solubility of the complex. The solubility of the complex in physiological fluids can, in turn, affect the tissue selectivity of the complex. Hydrophilic complexes tend to concentrate in the interstitial fluids, whereas hydrophobic complexes tend to associate with cells. Thus, differences in hydrophilicity can lead to different applications of the compounds. See, for example, Weinmann, et al., AJR, 142, 679 (Mar. 1984) and Brasch, et al., AJR, 142, 625 (Mar. 1984).
Thus, a need continues to exist for new and structurally diverse ionic and non-ionic complexes of paramagnetic ions for use as MRI agents. A further need also exists in the art to develop highly stable complexes with good relaxivity and low osmolar characteristics.
Summary of the Invention
The present invention provides novel complexing agents and complexes of complexing agents with paramagnetic ions for use in MRI. The complexes are represented by the two following general formulas:
Figure imgf000009_0002
Figure imgf000009_0003
wherein A is selected from the group consisting of
-CHR2CHOHCHR3- , -CHR2CHR3 [ (NCHR1COR8) CHR2CHR3] n- ,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2-; R8 is selected from the group consisting of -O-, -NR4OR5, -NR4O(CH2)nR6,
-NR4CH2CONR6CH2CH2OCH2R5, -NR4 (CH2) nNR5COCH2R6,
- (CH2)nCONR4CH2CONR6(CH2)nO(CH2)nOR5,
Figure imgf000009_0001
, and - (CH2)nCONR1(CH2)nCONR2R3; the R1, R2 and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl -such as for example methyl or ethyl wherein methyl is preferable to minimize lipophilicity, C1-8 alkoxy -such as for example methoxy or ethoxy, C1-8 mono- or poly- hydroxyalkyl -such as for example hydroxymethyl or dihydroxypropyl wherein dihydroxypropyl is preferred to enhance water solubility, C1-8 alkylalkoxy -such as for example methylmethoxy, C1-8 alkoxyalkyl - such as for example methoxymethyl or methoxyethyl wherein
methoxymethyl is preferred to reduce lipophilicity, and C5-8aryl - such as for example phenyl or benzyl, or wherein R2 and R3 as defined above together with the intervening carbon form a hydrocarbon ring of 5, 6 or 7 members.
Examples of possible R8 substituents include but are not limited to:
Figure imgf000010_0001
wherein the R4 , R5, R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl -such as for example methyl or ethyl wherein methyl is preferable to minimize lipophilicity, hydroxy, C1-8 alkoxy -such as for example methoxy or ethoxy , C1-8 mono- or poly- hydroxyalkyl -such as for example hydroxymethyl or dihydroxypropyl wherein dihydroxypropyl is preferred to enhance water solubility, C1-8 alkoxyalkyl -such as for example methoxymethyl or methoxyethyl wherein methoxymethyl is preferred to reduce lipophilicity, C1-8 aminoalkyl -such as for example aminomethyl, C5-10 aryl -such as for example phenyl or benzyl, C5-10 substituted aryl -such as for example aminophenyl or iodophenyl and C1-12 acylaminoalkyl -such as for example acetylaminomethyl; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of five, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are
-O-, -S- ,
Figure imgf000011_0001
or
,
Figure imgf000011_0002
and which members may be unsubstituted or substituted by hydrogen, C1-8 alkyl -such as for example methyl or ethyl wherein methyl is preferable to reduce lipophilicty, C5-10 aryl -such as for example phenyl or benzyl, C5-10 aminoaryl - such as for example aminophenyl or aminobenzyl, hydroxy, C1-8 alkoxy -such as for example methoxy or ethoxy, C1-8 mono- or poly- hydroxyalkyl -such as for example hydroxymethyl or hydroxyethyl, C1-8 alkoxyalkyl -such as for example methoxymethyl or methoxyethyl, C1-8 aminoalkyl -such as for example aminomethyl or aminoethyl, carbamoyl and C1-12 acylaminoalkyl -such as for example acetylaminomethyl or propanoylaminomethyl; n is an integer between 0 and 10; Mz+ is a paramagnetic ion of an element with an atomic number of 21-29, 42-44 or 58-79, and a valence Z of 2+, 3+ or 4+; (Z-r) of all the R8 groups are -0- and r is equal to 0, 1, 2, 3 or 4. According to the present invention in cases where
Mz+ is a heavy metal ion, such complexes can be used as X-ray contrast agents; if Mz+ is a radioactive isotope the complexes may be used as diagnostic or therapeutic agents in nuclear medicine.
The compounds of the present invention may also be attached to a biomolecule or polymeric compound. Examples of such compounds include biomolecules such as hormones, proteins, lipids, albumins, polyhydroxyl compounds such as amino sugars, carbohydrates and polylysines to name a few. The compounds of the present invention are attached to such a polymeric compound through the carboxyl group of the complexing acid or by other conventional methods.
The compounds of the present invention may also be carried by liposomes such as unilamellar or multilamellar vesicles and by other drug delivery systems. Also, disclosed is a diagnostic composition and a method of performing a diagnostic procedure which involves administering to a warm-blooded animal an effective amount of the above-described complex and then exposing the warm-blooded animal to a diagnostic procedure, thereby imaging at least a portion of the body of the warm-blooded animal.
Detailed Description of the Invention The complexing agents employed in this invention are derivatives of the well-known chelating agents such as DTPA, EDTA, CDTA or DOTA. In these derivatives, one or more of the carboxylic acid groups are converted to amide groups. Thus, for example, if the paramagnetic ion is trivalent, one or two of the carboxylic acid groups of DTPA may be derivatized to the amide form. Likewise, if the paramagnetic ion is divalent, one to three of the carboxylic acid groups of DTPA may be derivatized to the amide form. The same principle would be true if derivatives of other chelating agents such as EDTA, CDTA or DOTA were to be used.
The amide derivatives of chelating agents such as DTPA, EDTA, CDTA or DOTA are prepared in a conventional manner. In general, they are prepared by reacting a stoichiometric amount of a desired amine with a reactive derivative of a chelating agent under amide-forming conditions. Such reactive derivatives include, for example, anhydrides, mixed anhydrides and acid chlorides.
In one embodiment, the reactions are conducted in an organic solvent at an elevated temperature. Suitable solvents include those in which the reactants are sufficiently soluble and which are substantially unreactive with' the reactants and products. Lower aliphatic alcohols, ketone, ethers, esters, chlorinated hydrocarbons, toluene, xylene, lower aliphatic hydrocarbons, and the like may be advantageously used as reaction solvents. Examples of such solvents are methanol, ethanol, 2-propanol, 2-butanol, acetone, methylethylketone, diethylketone, methylacetate, ethylacetate, chloroform, methylenechloride, dichloroethane, hexane, heptane, octane, decane, and the like. If an acid chloride is used as a starting material, then the reaction solvent advantageously is one which does not contain reactive functional groups, such as hydroxyl groups, as these solvents can react with the acid chlorides, thus producing unwanted byproducts. The reaction temperature may vary widely, depending upon the starting materials employed, the nature of the reaction solvent and other reaction conditions. Such reaction temperatures may range, for example, from about 0°C to about 150°C preferably from about 30°C to about 70°C.
Following the reaction of the reactive derivative with the amine, any remaining anhydride or acid chloride groups can be hydrolyzed to the carboxylic groups by adding a stoichiometric excess of water to the reaction mixture and heating for a short time.
The resulting DTPA, EDTA, CDTA or DOTA amide is recovered from the reaction mixture by conventional procedures. For example, the product may be precipitated by adding a precipitating solvent to the reaction mixture and recovered by filtration or centrifugation.
The paramagnetic ion is then combined with the above isolated amide derivative under complex-forming conditions. In general, any of the paramagnetic ions referred to above can be employed in making the complexes of this invention. The complexes can conveniently be prepared by mixing a suitable oxide or salt to the paramagnetic ion with the complexing agent in aqueous solution. To assure complete complex formation, a slight stoichiometric excess of the complexing agent may be used. In addition, an elevated temperature, e.g., ranging from about 20°C to about 100°C, preferably from about 40°C to about 80°C, may be employed to insure complete complex formation. Generally, complete complex formation will occur within a period from a few minutes to a few hours after mixing. The complex may be recovered by precipitation using a precipitating solvent such as acetone, and further purified by crystallization, if desired. The novel complexes of this invention can be formulated into diagnostic compositions for enteral or parenteral administration. These compositions contain an effective amount of the paramagnetic ion complex along with conventional pharmaceutical carriers and excipients appropriate for the type of administration contemplated. For example, parenteral formulation advantageously contain a sterile aqueous solution or suspension of from about 0.05 to 1.0M of a paramagnetic ion complex according to this invention. Preferred parental formulations have a concentration of paramagnetic ion complex of 0.1M to 0.5M. Such solutions also may contain pharmaceutically acceptable buffers and, optionally, electrolytes such as sodium chloride. Advantageously, the compositions may further contain physiologically acceptable non-toxic cations in the form of suitable organic or inorganic salts, including suitable soluble complex salts with a chelate/ligand to enhance safety. Such chelates/ligands include the ligands set forth above used to complex paramagnetic and/or heavy metals to provide the complex formulations of this invention. Advantageously, the cation-ligand complex salt is provided in amounts ranging from about 0.001 Mol percent to about 15 Mol percent excess, of the ligand-metal complex. Examples of such physiologically acceptable non-toxic cations include sodium ions, calcium ions, magnesium ions, copper ions, zinc ions and the like including mixtures thereto. Calcium ions are preferred.
Parenteral compositions may be injected directly or mixed with a large volume parenteral composition for systemic administration.
Formulations for enteral administration may vary widely, as is well-known in the art. In general, such formulations are ligands which include an effective amount of the paramagnetic ion complex in aqueous solution or suspension. Such enteral compositions may optionally include buffers, surfactants, thixotropic agents, and the like. Compositions for oral administration may also contain flavoring agents and other ingredients for enhancing their organoleptic qualities.
The diagnostic compositions are administered in doses effective to achieve the desired enhancement of the MR image. Such doses may vary widely, depending upon the particular paramagnetic ion complex employed, the organs or tissues which are the subject of the imaging procedure, the MR imaging equipment being used, etc. In general, parenteral dosages will range from about 0.01 to about 1.0 MMol of paramagnetic ion complex per kilogram of patient body weight. Preferred parenteral dosage range from about 0.05 to about 0.5 MMol of the paramagnetic ion complex per kilogram of patient body weight. Enteral dosages generally range from about 0.5 to about 100 MMol, preferably from about 1.0 to about 20 MMol of paramagnetic ion complex per kilogram of patient body weight.
The novel MRI contrasting agents of this invention possess a unique combination of desirable features. The paramagnetic ion complexes exhibit a high solubility in physiological fluids, notwithstanding in some cases their substantially non-ionic character. This high solubility allows the preparation of concentrated solutions, thus minimizing the amount of fluid required to be administered. In selected cases the non-ionic character of the complex also reduces the osmolality of the diagnostic compositions, thus preventing undesired edema and other side effects.
The diagnostic compositions of this invention are used in the conventional manner. Compositions may be administered in a sufficient amount to provide adequate visualization, to a warm-blooded animal either systemically or locally to an organ or tissues to be imaged, and the animal then subjected to the MRI procedure. The compositions have been found to enhance the magnetic resonance images obtained by these procedures. In addition to their utility and magnetic resonance imaging procedures, the complexing agents of this invention may also be employed for delivery of radiopharmaceuticals or heavy metals for X-Ray contrast into the body. The invention is further illustrated by the following examples, which are not intended to be limiting.
EXAMPLE 1
Preparation of
{Aqua (N, N" -bis (N1111-2-methoxyethylcarbamoyl- methyl-N111-methylcarbaraoylmethyl ) diethylenetriamine-N, N' , N" -triacetate) }gadolinium( III) (4 )
Figure imgf000017_0001
The first step is a modified Schotten-Baumann acetylation of 2-methoxy-ethyl amine. The chloroamide, 1, is readily purified by vacuum distillation (1 torr, 58°C). Next, methylamine is N-alkylated with the chloroamide. The resulting N-methylglycine(2-methoxyethylamide), 2, is also purified by vacuum distillation (1 torr, 28°C). Reaction of the glycinamide with diethylenetriaminepentaacetic dianhydride in 2-propanol gives the desired bis(amide) of DTPA, 3. Complexation of the ligand with gadolinium gives the complex, 4. The complex is purified by reverse phase flash chromatography.
Experimental:
A) Chloro(N-(2-methoxyethyl))acetamide, (1)
In a three-necked 2L round bottom flask fitted with two 500mL addition funnels, containing 56.4g (39.8mL, 0.50mole) chloroacetyl chloride in 400mL dichloromethane and 20g (0.50mole) sodium hydroxide in 400mL water, respectively, and a water-cooled condenser, was placed 35.7g (41.3mL, 0.48mole) 2-methoxyethylamine, 100mL water, 100mL dichloro-methane. The reaction vessel was cooled to 0°C by a salt-ice bath. The organic and aqueous solutions were allowed to add slowly, ~0.25mL per minute, to the reaction mixture. During the addition the pH of the water phase of the reaction was monitored and the rate of addition of the alkali solution adjusted so as to maintain pH=12. When the addition was complete, the mixture was allowed to warm to room temperature and stir overnight. The organic layer was removed by siphon and dried with magnesium sulfate for four hours. The mixture was filtered through #4 filter paper on a large Buchner funnel and the sulfate washed with 2×100mL fresh dichloromethane. The combined filtrates were then placed in 2L round bottomed flask and the mixture distilled at 1 torr. Fractions collected from 55°C to 60°C were combined and analyzed by NMR. Yield 31.1g (43% based on starting 2-methoxyethylamine). TLC (silica on glass, 2% methanol in dichloromethane) Rf=0.40. 1H(δ,CDCl3) 3.28(s,3H), 3.40(m,4H), 3.97(s,2H), 6.92(br, 1H). 13C{1H} (δ, CDCl3) 39.27, 42.32, 58.60, 70.54, 166.22.
B) N'-(2-methoxyethyl)-N-methylglycinamide, (2)
To a 1L round bottom flask, fitted with reflux condenser and charged with 500mL 40% w/w aqueous methylamine, was added, with stirring, 31.1g (0.21mole) chloroamide, 1. The mixture was heated to 35°C and stirred overnight. To the mixture was added 8.8g (0.22mole) sodium hydroxide. The mixture was distilled at room pressure and the fraction boiling from 89°C to 98°C. The crude distillate was dried with magnesium sulfate and distilled again giving a clear colorless oil. Yield 13.9g (45% based on starting chloroamide, 1). TLC (silica on glass, 15% concentrated ammonium hydroxide in methanol) Rf=0.35. 1H(δ, CDCl3) 1.38(br, 1H), 2.32(s,3H), 3.14(s,2H), 3.26(s,3H), 3.37(m,4H), 7.35(br,1H). 13C{1H} (δ,CDCl3) 36.28, 38.39, 54.24, 58.53, 71.13, 171.62.
C) N,N"-bis(N""-2-methoxyethylcarbamoylmethyl-N"'- methylcarbamoylmethyl)diethylenetriammne-N,N',N"-triacetic acid, (3)
A 2L round bottom flask was charged with 13.9g (0.095mole) glycinamide, 2, 17.0g (0.047mole) diethylenetriaminepentaacetic dianhydride and 1L 2-propanol. The mixture was heated to 60°C and allowed to stir overnight. The mixture was cooled to room temperature, transferred, in 1L lots, to a 2L recovery flask and the solvent removed by means of a rotary- evaporater (water aspirator). To residue was added 10L distilled/deionized water, and the mixture filtered to remove diethylenetriaminepentaacetic acid. The water was removed by rotary evaporation giving an orange glass. Yield 34g (100%=30.9g based on starting anhydride). Typically, the ligand is used "as is" for complexometric reactions. A small sample was purified by reverse phase flash column chromatography. IR(cm-1) C-O 1724 (m,sh), 1659 (vs,). Anal. Calc. %C 48.07, %H 7.29, %N 15.09. Found %C 47.77, %H 7.04, %N 15.39.
D) {Aqua(N,N"-bis(N""-2-methoxyethylcarbamoylmethyl-N"'-methylcarbamoylmethyl)diethylenetriamine-N,N',N"-triacetate)}gadolinium(III), (4)
A 1L round bottom flask was charged with 34g (assuming 30.9g, 0.048mole anhydrous ligand present) crude ligand, 3, 8.6g (0.024mole) gadolinium oxide and 500mL water. The mixture was heated to gentle reflux and stirred overnight. The slightly turbid yellow mixture was filtered (0.42 micron) and concentrated to 50mL by rotary evaporator with a water aspirator. The thick clear solution was applied to a 5×35cm column loaded with YMC C-18 reverse phase packing. The column was eluted with water. Those fractions containing >98% pure complex, by HPLC with uv detector at 215nm, were combined, concentrated, filtered (0.42 micron) and evaporated to give a clear, colorless powder. Yield 20.5g (50% based on starting ligand, 3.) IR (cm-1) C=O 1676 (s,sh), 1620 (vs). Anal. Calc. for C26H46N7O12•3H2O %C 36.31, %H 6.09, %N 11.40, %Gd 18.29. Found %C 36.04, %H 5.90, %N 11.12, %Gd 17.79. Karl Fisher water calc. 5.91%, found 6.30%.
The mouse i .v . LD50 value of a 0 . 5M solution of {Aqua (N, N" -bis ( N" " -2 -methoxyethylcarbamoylmethyl -N ' " -methylcarbamoylmethyl)diethylenetriamine-N,N',N"-triacetate) }gadolinium( III) was determined to be 32 .5 mmol/kg (confidence limit of 27.3 - 38.8 mmol/kg) and the relaxivity rates (mmol-1sec-1) were obtained using the Bruker NMR Minispec (20 MHz) spectrometer at 40°C in both sterile water for injection (SWFI) and 4% bovine serum albumin (BSA): R1: SWFI, 4.3; BSA, 4.6; R2: SWFI, 4.1; BSA, 5.3.
EXAMPLE 2
A) N'-(2-Hydroxyethyl)-N-(2-hydroxyethyl)glycinamide(6)
Figure imgf000022_0001
Chloroacetyl chloride (56.7 g, 0.5 mol) was added dropwise to ethanolamine (160 g, 2.6 mol) in methylene chloride (150 ml) at ice water temperature and the mixture was allowed to stir at this temperature for 60 minutes and then at room temperature for 60 minutes. The solvent was removed by rotary evaporation. Ethanol (150 ml) was used to dissolve the residue. Sodium hydroxide pellets (40.0 g, 1.0 mol) were added to the mixture. The mixture was stirred at room temperature for 2 hours. Sodium chloride was removed by filtration. The filtrate was rotary evaporated under reduced pressure (<0.5 torr) to remove the ethanol, water, and ethanolamine. The crude product (72.3 g, 89%) was purified by C-18 chromatography using deionized water for elution. After the water was removed, the purified product was a colorless liquid: 1H NMR δ 2.7-2.8
(m, 2H), 3.3-3.5 (m, 4H), and 3.6-3.8 (m, 4H); C-13 NMR δ
177.6 (C=O), and 44.2, 52.9, 54.0, 63.0, and 63.4 representing 4 carbon atoms on two hydroxyethyl moieties and 1 methylene carbon atom on glycine moiety. B) N,N"-bis[N""-(2-hydroxyethyl)carbamoylmethyl-N'"-(2-hydroxyethyl)carbamoylmethyl]diethylenetriamine-N,N',N"-triacetic acid(7)
Figure imgf000023_0001
A slurry of 4.64 g (13.0 m mol) DTPA bisanhydrid in 20 ml dry dimethyl formamide (DMF) was prepared.
solution of 4.0 g (24.7 m mol) of the secondary amine (6) in 15 ml dry DMF was added dropwise to it. The mixture was stirred at room temperature for 60 minutes and then at 55°C for 2 hours. At the end of the reaction, 5 ml of water was added in order to digest the unreacted DTPA bisanhydride. The entire mixture was stirred at room temperature overnight. The solid formed (DTPA) was removed by filtration. The solvent was removed by rotary evaporation under reduced pressure. The DTPA bisamide (7) was purified from the residue by employing C-18 chromatography.
C) [N,N"-bis[N""-(2-hydroxyethyl)carbamoylmethyl-N'"-(2- hydroxyethyl)carbamoylmethyl]diethylenetriamine-N,N',N"- triacetate]]gadolinium(III) (8)
Figure imgf000024_0001
Gadolinium oxide (1.91 g, 5.27 m mol) was added to (7) (7.2 g, 10.6 m mol) in 50 ml of water. The mixture was stirred at 69°-71°C overnight. The solution was filtered and water was removed by rotary evaporation. The crude product (8) (9.2 g, 103.4%) was a white powder.
As various changes could be made in the above compounds and methods without departing from the scope of the invention, it is intended that all matter contained in the above description or shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

Claims

What is claimed is: 1. A complex comprising the following formula:
Figure imgf000025_0002
wherein A is selected from the group consisting of -CHR2CHOHCHR3-, -CHR2CHR3 [ (NCHR1COR8)CHR2CHR3]n-,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2-; R8 is selected from the group consisting of -O-, -NR4OR5,
-NR4O(CH2)nR6, -NR4CH2CONR6CH2CH2OCH2R5 , -NR4(CH2)nNR5 -COCH2R6, -(CH2)n-N4CH2CONR6(CH2)nO(CH2)nOR5,
Figure imgf000025_0001
and -(CH2)nCONR1(CH2)n
CONR2R3; the R1, R2 and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkylalkoxy, C1-8 alkoxyalkyl, and C5-8 aryl, or wherein R2 and R3 as defined above together with the intervening carbon form a
substituted or unsubstituted hydrocarbon ring of 5, 6 or 7 members, including:
Figure imgf000026_0001
wherein, the R4, R5, R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl and C1-12 acylaminoalkyl; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of five, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are
-O- -S- or
,
Figure imgf000026_0002
,
,
Figure imgf000026_0003
and which members may be unsubstituted or substituted by hydrogen, C1-8 alkyl, C5-10 aryl, C5-10 aminoaryl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl, carbamoyl and C1-12 acylaminoalkyl; n is an integer between 0 and 10; and Mz+ is a paramagnetic metal ion, a heavy metal ion or a radioactive isotope.
2. The complex of claim 1 wherein Mz+ is chromium (III), manganese (II), manganese (III), iron (III),
praseodymium (III), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), terbium (III), dysprosium (III), holmium (III) or erbium (III).
3. The complex of claim 1 wherein said complex is
attached to a biomolecule or polymeric compound selected from the group consisting of hormones, proteins, lipids, albumins, and polyhydroxyl
compounds such as amino sugars, carbohydrates or polysines.
4. A complex comprising the following formula:
Figure imgf000027_0002
wherein A is selected from the group consisting of -CHR2CHOHCHR3-, -CHR2CHR3[(NCHR1COR8)CHR2CHR3]n-,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2-; R8 is selected from the group consisting of -O-, -NR4OR5,
-NR4O(CH2)nR6, -NR4CH2CONR6CH2CH2OCH2R5, -NR4(CH2)nNR5 -COCH2R6, -(CH2)n-N4CH2CONR6(CH2)nO(CH2)nOR5,
Figure imgf000027_0001
and - (CH2)nCONR1(CH2)n
CONR2R3; the R1, R2 and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkylalkoxy, C1-8 alkoxyalkyl, and C5-8 aryl, or wherein R2 and R3 as defined above together with the intervening carbon form a substituted or unsubstituted hydrocarbon ring of 5, 6 or 7 members, including:
Figure imgf000028_0001
wherein, the R4, R5, R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl and C1-12 acylaminoalkyl; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of five, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are
-O- , -S-
Figure imgf000028_0002
or ,
Figure imgf000028_0003
and which members may be unsubstituted or
substituted by hydrogen, C1-8 alkyl, C5-10 aryl, C5-10 aminoaryl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl, carbamoyl and C1-12 acylaminoalkyl; n is an integer between 0 and 10; and Mz+ is a paramagnetic metal ion, a heavy metal ion or a radioactive isotope.
5. The complex of claim 4 wherein Mz+ is chromium (III), manganese (II), manganese (III), iron (III),
praseodymium (III), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), terbium (III), dysprosium (III), holmium (III) or erbium (III).
6. The complex of claim 4 wherein said complex is
attached to a biomolecule or polymeric compound selected from the group consisting of hormones, proteins, lipids, albumins, and polyhydroxye
compounds such as amino sugar, carbohydrates and polysines.
7. A diagnostic composition suitable for enteral or
parenteral administration to a warm-blooded animal, which comprises an MRI-effective amount of a complex of a paramagnetic ion comprising the following formula
Figure imgf000029_0001
wherein A is selected from the group consisting of -CHR2CHOHCHR3-, -CHR2CHR3[(NCHR1COR8)CHR2CHR3]n-,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2-; R8 is selected from the group consisting of -O-, -NR4OR5,
-NR4O(CH2)nR6, -NR4CH2CONR6CH2CH2OCH2R5, -NR4(CH2)nNR5 -COCH2R6, -(CH2)n-N4CH2CONR6(CH2)nO(CH2)nOR5,
Figure imgf000030_0001
and -(CH2)nCONR1(CH2)n CONR2R3; the R1, R2 and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkylalkoxy, C1-8 alkoxyalkyl, and C5-8 aryl, or wherein R2 and R3 as defined above together with the intervening carbon form a substituted or unsubstituted hydrocarbon ring of 5, 6 or 7 members, including:
Figure imgf000030_0002
wherein, the R4, R5, R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8
aminoalkyl and C1-12 acylaminoalkyl; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of five, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are
-O-, -S-, or
,
Figure imgf000031_0001
Figure imgf000031_0002
and which members may be unsubstituted or
substituted by hydrogen, C1-8 alkyl, C5-10 aryl, C5-10 aminoaryl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl, carbamoyl and C1-12 acylaminoalkyl; n is an integer between 0 and 10 and Mz+ is a paramagnetic metal ion, a heavy metal ion or a radioactive isotope; and a pharmaceutically acceptable carrier.
8. The diagnostic composition of claim 7 wherein Mz+ is chromium (III), manganese (II), manganese (III), iron (III), praseodymium (III), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), terbium (III), dysprosium (III), holmium (III) or erbium (III) .
9. The diagnostic composition of claim 7 wherein the complex is dissolved or suspended in a sterile aqueous pharmaceutically acceptable carrier at a concentration of from about .05 to 1.0 M.
10. The diagnostic composition of claim 7 which further contains a pharmaceutically acceptable buffer.
11. The diagnostic composition of claim 7 wherein said complex, is attached to a biomolecule or polymeric compound selected from the group consisting of hormones, proteins, lipids, albumins, and
polyhydroxyl compounds such as amino sugars, carbohydrates or polysines.
12. A diagnostic composition suitable for enteral or parenteral administration to a warm-blooded animal, which comprises an MRI-effective amount of a complex of a paramagnetic ion comprising the following formula:
Figure imgf000032_0002
wherein A is selected from the group consisting of -CHR2CHOHCHR3-, -CHR2CHR3[(NCHR1COR8)CHR2CHR3]n-,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2- ; R8 is selected from the group consisting of -O-, -NR4OR5,
-NR4O(CH2)nR6, -NR4CH2CONR6CH2CH2OCH2R5, -NR4(CH2)nNR5 -COCH2R6, -(CH2)n-N4CH2CONR6(CH2)nO(CH2)nOR5,
Figure imgf000032_0001
and -(CH2)nCONR1(CH2)n
CONR2R3; the R1, R2 and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkylalkoxy, C1-8 alkoxyalkyl, and C5-8 aryl, or wherein R2 and R3 as defined above together with the intervening carbon form a
substituted or unsubstituted hydrocarbon ring of 5, 6 or 7 members , including :
Figure imgf000033_0003
wherein, the R4, R5, R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl and C1-12 acylaminoalkyl; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of five, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are
-O- -S- or
, ,
Figure imgf000033_0001
,
Figure imgf000033_0002
and which members may be unsubstituted or
substituted by hydrogen, C1-8 alkyl, C5-10 aryl, C5-10 aminoaryl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl, carbamoyl and C1-12 acylaminoalkyl; n is an integer between 0 and 10 and Mz+ is a paramagnetic metal ion, a heavy metal ion or a radioactive isotope; and a pharmaceutically acceptable carrier.
13. The diagnostic composition of claim 12 wherein Mz+ is chromium (III), manganese (II), manganese (III), iron (III), praseodymium (III), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), terbium (III), dysprosium (III), holmium (III) or erbium (III).
14. The diagnostic composition of claim 12 wherein the complex is dissolved or suspended in a sterile aqueous pharmaceutically acceptable carrier at a concentration of from about .05 to 1.0 M.
15. The diagnostic composition of claim 12 which further contains a pharmaceutically acceptable buffer.
16. The diagnostic composition of claim 12 wherein said complex is attached to a biomolecule or polymeric compound selected from the group consisting of hormones, proteins, lipids, albumins, and
polyhydroxyl compounds such as amino sugars,
carbohydrates or polysines.
17. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of a complex of the formula:
Figure imgf000034_0001
wherein A is selected from the group consisting of -CHR2CHOHCHR3-, -CHR2CHR3[(NCHR1COR8)CHR2CHR3]n-,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2-; R8 is selected from the group consisting of -O-, -NR4OR5, -NR4O(CH2)nR6, -NR4CH2CONR6CH2CH2OCH2R5, -NR4(CH2)nNR5 -COCH2R6, -(CH2)n-N4CH2CONR6(CH2)nO(CH2)nOR5,
and - (CH2)nCONR1(CH2)n
Figure imgf000035_0001
CONR2R3; the R1, R2 and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkylalkoxy, C1-8 alkoxyalkyl, and C5-8 aryl, or wherein R2 and R3 as defined above together with the intervening carbon form a substituted or unsubstituted hydrocarbon ring of 5, 6 or 7 members, including:
Figure imgf000035_0002
wherein , the R4 , R5 , R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8
aminoalkyl and C1-12 acylaminoalkyl; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of five, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are
-O- -S- or
, ,
Figure imgf000036_0001
,
Figure imgf000036_0002
and which members may be unsubstituted or
substituted by hydrogen, C1-8 alkyl, C5-10 aryl, C5-10 aminoaryl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl, carbamoyl and C1-12 acylaminoalkyl; n is an integer between 0 and 10 and Mz+ is a paramagnetic metal ion, a heavy metal ion or a radioactive isotope; and a pharmaceutically acceptable carrier and then
exposing the animal to an imaging procedure, thereby imaging at least a portion of the body of the warm- blooded animal.
18. The method of claim 17 wherein Mz+ is chromium (III), manganese (II), manganese (III), iron (III),
praseodymium (III), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), terbium (III), dysprosium (III), holmium (III) or erbium (III).
19. The method of claim 17 wherein said complex is
attached to a biomolecule or polymeric compound selected from the group consisting of hormones, proteins, lipids, albumins, and polyhydroxyl
compounds such as amino sugars, carbohydrates or polysines.
20. A method of performing a diagnostic procedure, which comprises administering to a warm-blooded animal an effective amount of a complex of the formula:
Figure imgf000037_0002
wherein A is selected from the group consisting of -CHR2CHOHCHR3-, -CHR2CHR3[(NCHR1COR8)CHR2CHR3]n-,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2-; R8 is selected from the group consisting of -O-, -NR4OR5,
-NR4O(CH2)nR6, -NR4CH2CONR6CH2CH2OCH2R5, -NR4(CH2)nNR5 -COCH2R6, -(CH2)n-N4CH2CONR6(CH2)nO(CH2)nOR5,
Figure imgf000037_0001
and - (CH2)nCONR1(CH2)n
CONR2R3; the R1, R2 and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkylalkoxy, C1-8 alkoxyalkyl, and C5-8 aryl, or wherein R2 and R3 as defined above
together with the intervening carbon form a
substituted or unsubstituted hydrocarbon ring of 5, 6 or 7 members, including:
, ,
Figure imgf000037_0005
,
Figure imgf000037_0003
Figure imgf000037_0004
and
,
Figure imgf000038_0004
Figure imgf000038_0003
Figure imgf000038_0005
, wherein, the R4, R5, R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl and C1-12 acylaminoalkyl; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of five, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are
-O- , -S- , or
Figure imgf000038_0001
,
Figure imgf000038_0002
and which members may be unsubstituted or
substituted by hydrogen, C1-8 alkyl, C5-10 aryl, C5-10 aminoaryl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl, carbamoyl and C1-12 acylaminoalkyl; n is an integer between 0 and 10 and W is a paramagnetic metal ion, a heavy metal ion or a radioactive isotope; and a pharmaceutically acceptable carrier and then exposing the animal to an imaging procedure, thereby imaging at least a portion of the body of the warm- blooded animal.
21. The method of claim 20 wherein Mz+ is chromium (III), manganese (II), manganese (III), iron (III),
praseodymium (III), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), terbium (III), dysprosium (III), holmium (III) or erbium (III).
22. The method of claim 20 wherein said complex is
attached to a biomolecule or polymeric compound selected from the group consisting of hormones, proteins, lipids, albumins, and polyhydroxyl
compounds such as amino sugar, carbohydrates or polysines.
23. A complexing agent comprising the following formula:
Figure imgf000039_0002
wherein A is selected from the group consisting of -CHR2CHOHCHR3-, -CHR2CHR3[(NCHR1COR8)CHR2CHR3]n-,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2-; R8 is selected from the group consisting of -O-, -NR4OR5,
-NR4O(CH2)nR6, -NR4CH2CONR6CH2CH2OCH2R5, -NR4(CH2)nNR5 -COCH2R6, -(CH2)n-N4CH2CONR6(CH2)nO(CH2)nOR5,
and -(CH2)nCONR1(CH2)n
Figure imgf000039_0001
CONR2R3; the R1, R2 and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkylalkoxy, C1-8 alkoxyalkyl, and C5-8 aryl, or wherein R2 and R3 as defined above together with the intervening carbon form a substituted or unsubstituted hydrocarbon ring of 5, 6 or 7 members, including:
Figure imgf000040_0003
wherein, the R4, R5, R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl and C1-12 acylaminoalkyl; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of five, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are -O- , -S- ,
Figure imgf000040_0001
or ,
Figure imgf000040_0002
and which members may be unsubstituted or
substituted by hydrogen, C1-8 alkyl, C5-10 aryl, C5-10 aminoaryl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl, carbamoyl and C1-12 acylaminoalkyl; n is an integer between 0 and 10; and Mz+ is a paramagnetic metal ion, a heavy metal ion or a radioactive isotope.
24. The complexing agent of claim 23 wherein said agent is attached to a biomolecule or polymeric compound selected from the group consisting of hormones, proteins, lipids, albumins, and polyhydroxyl compounds such as amino sugars, carbohydrates or polysines.
25. A complexing agent comprising the following formula:
Figure imgf000041_0001
wherein A is selected from the group consisting of
-CHR2CHOHCHR3-, -CHR2CHR3[(NCHR1COR8)CHR2CHR3]n-,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2-; R8 is selected from the group consisting of -O-, -NR4OR5,
-NR4O(CH2)nR6, -NR4CH2CONR6CH2CH2OCH2R5, -NR4(CH2)nNR5 -COCH2R6, -(CH2)n-N4CH2CONR6(CH2)nO(CH2)nOR5, (CH2)nCONR4(CH2)nCH,CONQθ and -(CHC)nCONR1(CH2)n
CONR2R3; the R1, R2 and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkylalkoxy, C1-8 alkoxyalkyl, and C1-8 aryl, or wherein R2 and R3 as defined above together with the intervening carbon form a substituted or unsubstituted hydrocarbon ring of 5, 6 or 7 members, including:
Figure imgf000042_0001
wherein, the R4, R5, R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl and C1-12 acylaminoalkyl; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of five, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are
-O- or
, -S- ,
Figure imgf000043_0002
,
Figure imgf000043_0003
and which members may be unsubstituted or
substituted by hydrogen, C1-8 alkyl, C5-10 aryl, C5-10 aminoaryl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl, carbamoyl and C1-12 acylaminoalkyl; n is an integer between 0 and 10; and Mz+ is a paramagnetic metal ion, a heavy metal ion or a radioactive isotope.
26. The complexing agent of claim 25 wherein said
complex is attached to a biomolecule or polymeric compound selected from the group consisting of hormones, proteins, lipids, albumins, and
polyhydroxyl compounds such as amino sugars, carbohydrates or polysines.
27. A diagnostic composition suitable for enteral or parenteral administration to a warm-blooded animal, which comprises an imaging-effective amount of a complex of a heavy metal ion comprising the following formula:
Figure imgf000043_0001
wherein A is selected from the group consisting of -CHR2CHOHCHR3-, -CHR2CHR3[(NCHR1COR8)CHR2CHR3]n-,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2-; R8 is selected from the group consisting of -O-, -NR4OR5, -NR4O(CH2)nR6, -NR4CH2CONR6CH2CH2OCH2R5, -NR4(CH2)nNR5 -COCH2R6, - (CH2)n-N4CH2CONR6(CH2)nO(CH2)nOR5,
and -(CH2)nCONR1(CH2)n
Figure imgf000044_0002
CONR2R3; the R1, R2 and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkylalkoxy, C1-8 alkoxyalkyl, and C5-8 aryl, or wherein R2 and R3 as defined above together with the intervening carbon form a
substituted or unsubstituted hydrocarbon ring of 5, 6 or 7 members, including:
Figure imgf000044_0001
wherein, the R4, R5, R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8
aminoalkyl and C1-12 acylaminoalkyl; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of five, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are
-O- , -S- , or
Figure imgf000045_0001
,
Figure imgf000045_0002
and which members may be unsubstituted or
substituted by hydrogen, C1-8 alkyl, C5-10 aryl, C5-10 aminoaryl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl, carbamoyl and C1-12 acylaminoalkyl; n is an integer between 0 and 10 and Mz+ is a heavy metal ion; and a pharmaceutically acceptable carrier.
28. The diagnostic composition of claim 27 wherein said complex is attached to a biomolecule or polymeric compound selected from the group consisting of hormones, proteins, lipids, albumins, and
polyhydroxyl compounds such as amino sugars, carbohydrates or polysines.
29. The diagnostic composition of claim 27 wherein Mz+ is lead, bismuth or barium.
30 . The diagnostic composition of claim 27 wherein the complex is dissolved or suspended in a sterile aqueous pharmaceutically acceptable carrier at a concentration of from about .05 to 1 . 0 M.
31 . The diagnostic composition of claim 27 which further contains a pharmaceutically acceptable buffer .
32 . A diagnostic composition suitable for enteral or parenteral administration to a warm-blooded animal , which comprises an imaging-effective amount of a complex of a heavy metal ion comprising the
following formula :
Figure imgf000046_0002
wherein A is selected from the group consisting of -CHR2CHOHCHR3-, -CHR2CHR3[(NCHR1COR8)CHR2CHR3]n-,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2- ; R8 is selected from the group consisting of -O-, -NR4OR5,
-NR4O(CH2)nR6, -NR4CH2CONR6CH2CH2OCH2R5, -NR4(CH2)nNR5 -COCH2R6, -(CH2)n-N4CH2CONR6(CH2)nO(CH2)nOR5,
Figure imgf000046_0001
and -(CH2)nCONR1(CH2)n
CONR2R3; the R1, R2 and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkylalkoxy, C1-8 alkoxyalkyl, and C5-8 aryl, or wherein R2 and R3 as defined above together with the intervening carbon form a substituted or unsubstituted hydrocarbon ring of 5, 6 or 7 members, including:
Figure imgf000047_0001
wherein, the R4 , R5, R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl , hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl , C1-8 alkoxyalkyl , C1-8 aminoalkyl and C1-12 acylaminoalkyl ; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of f ive, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are
-O- -S- or
, ,
Figure imgf000047_0002
,
Figure imgf000047_0003
and which members may be unsubstituted or
substituted by hydrogen, C1-8 alkyl, C5-10 aryl, C5-10 aminoaryl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl, carbamoyl and C1-12 acylaminoalkyl; n is an integer between 0 and 10 and Mz+ is a heavy metal ion; and a pharmaceutically acceptable carrier.
33. The diagnostic composition of claim 32 wherein said complex is attached to a biomolecule or polymeric compound selected from the group consisting of hormones, proteins, lipids, albumins, and
polyhydroxyl compounds such as amino sugars, carbohydrates or polysines.
34. The diagnostic composition of claim 32 wherein Mz+ is lead, bismuth or barium.
35. The diagnostic composition of claim 32 wherein the complex is dissolved or suspended in a sterile aqueous pharmaceutically acceptable carrier at a concentration of from about .05 to 1.0 M.
36. The diagnostic composition of claim 32 which further contains a pharmaceutically acceptable buffer.
37. A diagnostic composition suitable for enteral or
parenteral administration to a warm-blooded animal, which comprises an imaging-effective amount of a radioactive isotope comprising the following
formula:
Figure imgf000049_0002
wherein A is selected from the group consisting of -CHR2CHOHCHR3-, -CHR2CHR3[(NCHR1COR8)CHR2CHR3]n-,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2-; R8 is selected from the group consisting of -O-, -NR4OR5, -NR4O(CH2)nR6, -NR4CH2CONR6CH2CH2OCH2R5, -NR4(CH2)nNR5 -COCH2R6, -(CH2)n-N4CH2CONR6(CH2)nO(CH2)nOR5,
and -(CH2)nCONR1(CH2)n
Figure imgf000049_0001
CONR2R3; the R1, R2 and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkylalkoxy, C1-8 alkoxyalkyl, and C5-8 aryl, or wherein R2 and R3 as defined above together with the intervening carbon form a
substituted or unsubstituted hydrocarbon ring of 5, 6 or 7 members, including:
Figure imgf000049_0003
wherein, the R4, R5, R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8
aminoalkyl and C1-12 acylaminoalkyl; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of five, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are
-O- , -S-
Figure imgf000050_0001
or
, ,
Figure imgf000050_0002
and which members may be unsubstituted or
substituted by hydrogen, C1-8 alkyl, C5-10 aryl, C5-10 aminoaryl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl, carbamoyl and C1-12 acylaminoalkyl; n is an integer between 0 and 10 and Mz+ is a radioactive isotope; and a pharmaceutically acceptable carrier.
38. The diagnostic composition of claim 37 wherein said complex is attached to a biomolecule or polymeric compound selected from the group consisting of hormones, proteins, lipids, albumins, and
polyhydroxyl compounds such as amino sugars, carbohydrates or polysines.
39. The diagnostic composition of claim 37 wherein Mz+ is rhenium.
40. The diagnostic composition of claim 37 wherein the complex is dissolved or suspended in a sterile aqueous pharmaceutically acceptable carrier at a concentration of from about .05 to 1.0 M.
41. The diagnostic composition of claim 37 which further contains a pharmaceutically acceptable buffer.
42. A diagnostic composition suitable for enteral or
parenteral administration to a warm-blooded animal, which comprises an imaging-effective amount of a radioactive isotope comprising the following
formula:
Figure imgf000051_0002
wherein A is selected from the group consisting of -CHR2CHOHCHR3-, -CHR2CHR3[ (NCHR1COR8)CHR2CHR3]n- ,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2-; R8 is selected from the group consisting of -O-, -NR4OR5,
-NR4O(CH2)nR6, -NR4CH2CONR6CH2CH2OCH2R5 , -NR4(CH2)nNR5 -COCH2R6, -(CH2)n-N4CH2CONR6(CH2)nO(CH2)nOR5,
Figure imgf000051_0001
and - (CH2)nCONR1(CH2)n
CONR2R3; the R1, R2 and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkylalkoxy, C1-8 alkoxyalkyl, and C5-8 aryl, or wherein R2 and R3 as defined above together with the intervening carbon form a
substituted or unsubstituted hydrocarbon ring of 5,
6 or 7 members, including:
Figure imgf000052_0001
wherein, the R4, R5, R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl and C1-12 acylaminoalkyl; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of five, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are
-O-
Figure imgf000052_0002
or
, -S-, ,
Figure imgf000052_0003
and which members may be unsubstituted or substituted by hydrogen , C1-8 alkyl , C5-10 aryl , C5-10 aminoaryl , hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl , C1-8 alkoxyalkyl , C1-8 aminoalkyl , carbamoyl and C1-12 acylaminoalkyl ; n is an integer between 0 and 7 and Mz+ is a radioactive isotope ; an a pharmaceutically acceptable carrier .
43. The diagnostic composition of claim 42 wherein said complex is attached to a biomolecule or polymeric compound selected from the group consisting of hormones, proteins, lipids, albumins, and
polyhydroxyl compounds such as amino sugars, carbohydrates or polysines.
44. The diagnostic composition of claim 42 wherein Mz+ is rhenium.
45. The diagnostic composition of claim 42 wherein the complex is dissolved or suspended in a sterile aqueous pharmaceutically acceptable carrier at a concentration of from about .05 to 1.0 M.
46. The diagnostic composition of claim 42 which further contains a pharmaceutically acceptable buffer.
47. A therapeutic composition suitable for enteral or parenteral administration to a warm-blooded animal, which comprises a therapeutically-effective amount of a radioactive isotope comprising the following formula:
Figure imgf000053_0001
wherein A is selected from the group consisting of -CHR2CHOHCHR3-, -CHR2CHR3[(NCHR1COR8)CHR2CHR3]n-,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2-; R8 is selected from the group consisting of -O-, -NR4OR5, -NR4O(CH2)nR6, -NR4CH2CONR6CH2CH2OCH2R5, -NR4(CH2)nNR5 -COCH2R6, -(CH2)n-N4CH2CONR6(CH2)nO(CH2)nOR5,
Figure imgf000054_0002
and - (CH2)nCONR1(CH2)n
CONR2R3; the R1, R: and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkylalkoxy, C1-8 alkoxyalkyl, and C5-8 aryl, or wherein R2 and R3 as defined above together with the intervening carbon form a substituted or unsubstituted hydrocarbon ring of 5, 6 or 7 members, including:
Figure imgf000054_0001
wherein, the R4, R5, R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8
aminoalkyl and C1-12 acylaminoalkyl; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of five, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are
- O- -S- or
, ,
Figure imgf000055_0001
,
Figure imgf000055_0002
and which members may be unsubstituted or
substituted by hydrogen, C1-8 alkyl, C5-10 aryl, C5-10 aminoaryl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl, carbamoyl and C1-12 acylaminoalkyl; n is an integer between 0 and 10 and Mz+ is a radioactive isotope; and a pharmaceutically acceptable carrier.
48. The therapeutic composition of claim 47 wherein said complex is attached to a biomolecule or polymeric compound selected from the group consisting of hormones, proteins, lipids, albumins, and
polyhydroxyl compounds such as amino sugars, carbohydrates or polysines.
49. The therapeutic composition of claim 47 wherein Mz+ is rhenium.
50. The therapeutic composition of claim 47 wherein the complex is dissolved or suspended in a sterile aqueous pharmaceutically acceptable carrier at a concentration of from about .05 to 1.0 M.
51. The therapeutic composition of claim 47 which
further contains a pharmaceutically acceptable buffer.
52. A therapeutic composition suitable for enteral or parenteral administration to a warm-blooded animal, which comprises a therapeutically-effective amount of a radioactive isotope comprising the following formula:
Figure imgf000056_0002
wherein A is selected from the group consisting of -CHR2CHOHCHR3-, -CHR2CHR3[(NCHR1COR8)CHR2CHR3]n-,
-CHR2CHR3OCH2CH2- and -CH2CHR2OCHR3CH2-; R8 is selected from the group consisting of -O-, -NR4OR5,
-NR4O(CH2)nR6, -NR4CH2CONR6CH2CH2OCH2R5, -NR4(CH2)nNR5 -COCH2R6, -(CH2)n-N4CH2CONR6(CH2)rO(CH2)nOR5,
Figure imgf000056_0001
and -(CH2)nCONR2(CH2)n
CONR2R3; the R1, R2 and R3 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkylalkoxy, C1-8 alkoxyalkyl, and C5-8 aryl, or wherein R2 and R3 as defined above together with the intervening carbon form a
substituted or unsubstituted hydrocarbon ring of 5, 6 or 7 members, including:
Figure imgf000057_0003
wherein, the R4, R5, R6 and R7 groups may be the same or different selected from the group consisting of hydrogen, C1-8 alkyl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8
aminoalkyl and C1-12 acylaminoalkyl; the R5 and R6 groups together with the adjacent nitrogen can form a heterocyclic ring of five, six or seven members wherein 0 to 2 members of the ring other than the nitrogen are
-O- or
, -S-,
Figure imgf000057_0001
,
Figure imgf000057_0002
and which members may be unsubstituted or substituted by hydrogen, C1-8 alkyl, C5-10 aryl, C5-10 aminoaryl, hydroxy, C1-8 alkoxy, C1-8 mono- or poly- hydroxyalkyl, C1-8 alkoxyalkyl, C1-8 aminoalkyl, carbamoyl and C1-12 acylaminoalkyl; n is an integer between 0 and 10 and Mz+ is a radioactive isotope; and a pharmaceutically acceptable carrier.
53. The therapeutic composition of claim 52 wherein said complex is attached to a biomolecule or polymeric compound selected from the group consisting of hormones, proteins, lipids, albumins, and
polyhydroxyl compounds such as amino sugars, carbohydrates or polysines.
54. The therapeutic composition of claim 52 wherein Mz+ is rhenium.
55. The therapeutic composition of claim 52 wherein the complex is dissolved or suspended in a sterile aqueous pharmaceutically acceptable carrier at a concentration of from about .05 to 1.0 M.
56. The therapeutic composition of claim 52 which
further contains a pharmaceutically acceptable buffer.
PCT/US1993/009868 1992-10-13 1993-10-13 Novel compositions for magnetic resonance imaging WO1994008630A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU53609/94A AU5360994A (en) 1992-10-13 1993-10-13 Novel compositions for magnetic resonance imaging

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95989692A 1992-10-13 1992-10-13
US07/959,896 1992-10-13

Publications (1)

Publication Number Publication Date
WO1994008630A1 true WO1994008630A1 (en) 1994-04-28

Family

ID=25502555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/009868 WO1994008630A1 (en) 1992-10-13 1993-10-13 Novel compositions for magnetic resonance imaging

Country Status (2)

Country Link
AU (1) AU5360994A (en)
WO (1) WO1994008630A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693308A (en) * 1996-02-21 1997-12-02 Mallinckrodt Medical, Inc. Magnetic resonance blood pool agents bound to human serum albumin

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687658A (en) * 1984-10-04 1987-08-18 Salutar, Inc. Metal chelates of diethylenetriaminepentaacetic acid partial esters for NMR imaging
US4687659A (en) * 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
EP0255471A1 (en) * 1986-07-28 1988-02-03 Schering Aktiengesellschaft 1,4,7,10-Tetraazacyclododecane-derivatives
DE3633245A1 (en) * 1986-09-26 1988-03-31 Schering Ag Cyclic amide complexes
WO1990001024A1 (en) * 1988-07-19 1990-02-08 Mallinckrodt, Inc. Novel magnetic resonance imaging agents
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4980148A (en) * 1985-02-06 1990-12-25 Mallinckrodt, Inc. Methods for enhancing magnetic resonance imaging
US5011925A (en) * 1989-03-09 1991-04-30 Mallinckrodt, Inc. Morpholinoamido EDTA derivatives
EP0450742A1 (en) * 1990-04-06 1991-10-09 Schering Aktiengesellschaft DTPA-Monoamids, pharmaceutical compositions containing them, their use and process for their preparation
US5087440A (en) * 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
US5094950A (en) * 1988-06-07 1992-03-10 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
US5138040A (en) * 1991-07-02 1992-08-11 Mallinckrodt Medical, Inc. Composition for magnetic resonance imaging
US5141740A (en) * 1990-11-21 1992-08-25 Mallinckrodt Medical, Inc. Complexes and compositions for magnetic resonance imaging and usage methods
EP0512661A1 (en) * 1991-05-10 1992-11-11 Schering Aktiengesellschaft Macrocyclic polymer-complexing, their complexes, method for their production and pharmaceutical agents containing them

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4687658A (en) * 1984-10-04 1987-08-18 Salutar, Inc. Metal chelates of diethylenetriaminepentaacetic acid partial esters for NMR imaging
US4687659A (en) * 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US4980148A (en) * 1985-02-06 1990-12-25 Mallinckrodt, Inc. Methods for enhancing magnetic resonance imaging
EP0255471A1 (en) * 1986-07-28 1988-02-03 Schering Aktiengesellschaft 1,4,7,10-Tetraazacyclododecane-derivatives
DE3633245A1 (en) * 1986-09-26 1988-03-31 Schering Ag Cyclic amide complexes
US5094950A (en) * 1988-06-07 1992-03-10 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
WO1990001024A1 (en) * 1988-07-19 1990-02-08 Mallinckrodt, Inc. Novel magnetic resonance imaging agents
US5137711A (en) * 1988-07-19 1992-08-11 Mallickrodt Medical, Inc. Paramagnetic dtpa and edta alkoxyalkylamide complexes as mri agents
US5011925A (en) * 1989-03-09 1991-04-30 Mallinckrodt, Inc. Morpholinoamido EDTA derivatives
US5087440A (en) * 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
EP0450742A1 (en) * 1990-04-06 1991-10-09 Schering Aktiengesellschaft DTPA-Monoamids, pharmaceutical compositions containing them, their use and process for their preparation
US5141740A (en) * 1990-11-21 1992-08-25 Mallinckrodt Medical, Inc. Complexes and compositions for magnetic resonance imaging and usage methods
EP0512661A1 (en) * 1991-05-10 1992-11-11 Schering Aktiengesellschaft Macrocyclic polymer-complexing, their complexes, method for their production and pharmaceutical agents containing them
US5138040A (en) * 1991-07-02 1992-08-11 Mallinckrodt Medical, Inc. Composition for magnetic resonance imaging

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693308A (en) * 1996-02-21 1997-12-02 Mallinckrodt Medical, Inc. Magnetic resonance blood pool agents bound to human serum albumin

Also Published As

Publication number Publication date
AU5360994A (en) 1994-05-09

Similar Documents

Publication Publication Date Title
JP2815556B2 (en) Nonionic paramagnetic ionic complex and complexing agent for forming the same
US5077037A (en) Novel compositions for magnetic resonance imaging
US5417959A (en) Functionalized aza-crytand ligands for diagnostic imaging applications
US5011925A (en) Morpholinoamido EDTA derivatives
US5141740A (en) Complexes and compositions for magnetic resonance imaging and usage methods
US5405601A (en) Functionalized tripodal ligands for imaging applications
US5162109A (en) Magnetic resonance imaging agents
US5138040A (en) Composition for magnetic resonance imaging
AU640140B2 (en) Novel magnetic resonance imaging agents
US5290537A (en) Compositions for magnetic resonance imaging
US5217706A (en) Complexes and compositions for magnetic resonance imaging
AU656355B2 (en) Alkoxyamide derivatized chelates for MRI
WO1994008630A1 (en) Novel compositions for magnetic resonance imaging
US5961953A (en) Magnetic resonance blood pool agents
AU650615C (en) Novel magnetic resonance imaging agents
WO1995032004A1 (en) Functionalized bicyclo[2.2.1] heptane and [2.2.2] octane system as preorganized ligands for imaging applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA FI JP KP NO PL

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase